|
Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
Jae-Ho Yoon, Seok Lee
Korean J Intern Med. 2024;39(1):34-56. Published online January 1, 2024
Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological malignancies with advanced understanding of the genetic landscape, detection methods of minimal residual disease (MRD), and the development of immunotherapeutic agents with good clinical outcomes. The annual inciden..
|
|
|
Pulmonology
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
Soo Han Kim, Eun Jung Jo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Jung Seop Eom, Mi-Hyun Kim
Korean J Intern Med. 2023;38(2):218-225. Published online February 21, 2023
Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce.
Methods: This retrospective study included 89 patients with ES-SCLC treated with ..
|
|
|
Hemato-oncology
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2021;36(4):975-984. Published online April 6, 2021
Background/Aims: Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer.
Methods: This study included patients with non-small cell..
|
|
|
Gastroenterology
Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Korean J Intern Med. 2020;35(5):1104-1113. Published online April 21, 2020
Background/Aims: The optimal timing for initiation of anti-tumor necrosis factor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about the clinical outcomes of early versus late administration of anti-TNF agents, especially in Asian CD patients. We aimed to evaluate the imp..
|
|
|
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
Inkeun Park, Jae Lyun Lee
Korean J Intern Med. 2020;35(4):834-853. Published online July 1, 2020
After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial cancer (mUC), very little progress has been made in the treatment landscape of this condition until recently. With increased knowledge about the molecular biology of mUC and advances in the field of cancer imm..
|
|
|
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Kyung-Ann Lee, Hae-Rim Kim, So Young Yoon
Korean J Intern Med. 2019;34(6):1197-1209. Published online April 25, 2019
Immune checkpoint inhibitors (ICIs) have revolutionized anticancer therapy due to their long-term clinical benefits and immune boosting mechanisms. However, despite their consistent therapeutic effects, the use of ICIs is associated with a spectrum of adverse events due to their autoimmune and auto-..
|
|
|
Cellular immunotherapy in multiple myeloma
Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Sung-Hoon Jung, Duck Cho, Hye-Seong Park, Tan-Huy Chu, Hyun-Ju Lee, Hyeoung-Joon Kim, Sang-Ki Kim, Je-Jung Lee
Korean J Intern Med. 2019;34(5):954-965. Published online February 15, 2019
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic..
|
|
|
Hemato-oncology
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Sung Won Lim, Myung-Ju Ahn
Korean J Intern Med. 2019;34(1):50-59. Published online September 3, 2018
Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). Applications of targeted therapy, such as an epidermal g..
|
|
|
Targeted therapy of ovarian cancer including immune check point inhibitor
Jin Young Kim, Chi Heum Cho, Hong Suk Song
Korean J Intern Med. 2017;32(5):798-804. Published online August 22, 2017
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate o..
|
|
|
